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Abstract. Up to a couple of years ago, the 33S (n, α)30S i cross-section data had been limited and scarce. The
origin in the solar system of 36S had been the only motivation to study that cross-section. However, a few
years ago, the 33S (n, α)30S i reaction was proposed as a possible target in neutron capture therapy (NCT) due
to the excellent bio-properties of 33S and the significant resonance at 13.45 keV of the cross-section for which
a high-energy α is emitted. Prior to the experiments carried out at n_TOF-CERN and at the Institut Laue-
Langevin (ILL) facilities, the data situation was: no data from the thermal point up to 10 keV; from 10 keV
to 300 keV, there was only one (n, α) measurement able to resolve the resonances with a questionable value
of the 13.45-keV resonance; and the thermal point did not have a consistent value. Here we summarize three
experiments that have been performed covering the whole energy range of interest in NCT and astrophysics.
These experiments have solved the most important issues. The data of the present work and the evaluated data
are used to calculate the dose rate in the tissue.
1 Introduction
The quantity and the quality of nuclear data in a given re-
action depend on several issues such as the field of appli-
cation and the request accuracy. Up to a few years ago,
the 33S (n, α)30S i cross-section had been only a role in as-
trophysics due to the origin of the neutron-rich isotope 36S
[1, 2], which remains an open question [3]. Few years ago,
a possible application of the 33S (n, α)30S i reaction to neu-
tron capture therapy (NCT) was proposed by Porras [4].
NCT is a type of experimental radiotherapy whose ob-
jective is the selective destruction of tumor cells with high-
energy light ions emitted by means of neutron capture in a
target element. For this purpose, a binary method is used
which combines the absorption of a defined neutron target
by tumor cells and the subsequent radiation with neutrons
of the tumor area [5].
NCT studies have been focused on 10B as target for
neutrons because of several reasons: a very high thermal
cross-section of neutron capture with emission of light
ions, a high positive Q-value (2.79 MeV) [6] and boron
compounds which are absorbed by tumor cells in a greater
proportion than in normal cells with a maximum of 3:1
[7]. Therefore, in boron neutron capture therapy (BNCT),
a beam of thermal neutrons (En < 0.5 eV) [8] is captured
by boron within tumor cells with the subsequent emission
of light ions (α and 7Li) with a high linear energy transfer
(LET) in a spatial range within a cell size [5].
IAEA established the figures of merit of a neutron
beam suitable for NCT [8]. Briefly, three energetic groups
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for thermal (En < 0.5 eV), epithermal (0.5 eV < En < 10
keV) and fast (En > 10 keV) neutrons were defined and
the recommendation for the fluxes (Φ) are the following:
Φth ≥ 109 n·cm−2·s−1 with Φth/Φtot ≥ 0.9 for shallow tu-
mors, and Φepi ≥ 109 n·cm−2·s−1 with Φepi/Φth ≥ 100 and
Φepi/Φ f ast ≥ 20 for deep tumors.
The 33S interest in NCT is due to: a very large res-
onance at 13.45 keV, with emission of light ions with a
value greater than 10B(n, α)7Li [2]; a very high positive Q-
value (3.49 MeV), higher than 10B [6]; and in relation to
compounds that transport 33S to tumor cells, a high absorp-
tion of 35S in tumor cell has already been observed in mice
in in vivo experiments [9]. Unlike boron, sulfur is one of
the essential elements of living matter and is part of count-
less compounds that play an important biological role. It
is present in the aminoacids cysteine and methionine, in
peptides and proteins. Sulfur plays a fundamental role in
the synthesis of glutathione, from L-cysteine. The mea-
sured concentrations of glutathione in tumor cells are usu-
ally high and, in fact, it is considered an important factor
in tumor resistance to chemotherapy [10]. The possibility
of selectively incorporating a sulfur isotope by glutathione
precursors is very promising.
Hence, the status of the 33S (n, α)30S i cross-section
data, before the role in NCT was proposed, was the follow-
ing: there was no data from the thermal point up to 10 keV,
the most important range for NCT with the present IAEA
recommendations; there was only one (n, α) measurement
able to resolve resonances [2] which encompassed from
10 keV to 1 MeV, and the thermal point did not have a
consistent value due to the few dissenting existing values
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ranging from 8 to 180 mb [11–14]. In addition, the most
important resonance value (13.45 keV), which is essential
for the possible use of 33S in NCT, was questioned because
of the discrepancies in the resonance parameters between
Wagemans et al. [2] and the transmission measurement of
Coddens et al. [15]. Both experiments were carried out in
different facilities but the analysis was performed in col-
laboration. The Γα parameter of the 13.45 keV resonance
provided by Coddens et al. was a factor two that of Wage-
mans et al. [2, 15]. This discrepancy is crucial for NCT
because it means that the dose rate could be double in the
same treatment conditions (neutron fluence and 33S con-
centration).
On the other hand, it should be noticed that the most
relevant resonance located at 13.45 keV, which is funda-
mental for the possible use of 33S in NCT, is not in the
range of epithermal neutrons (up to 10 keV). However, this
limit was established by IAEA with the experience of neu-
tron beams in nuclear reactors and it is expected to be mod-
ified with the new generation of accelerator-based neutron
sources (ABNS) under development in few projects world-
wide [16]. Indeed, it has already been shown that the range
where neutrons are considered suitable for human tissue
can be increased up to 20 keV [17] or 40 keV [18].
Therefore, new measurements, which would provide
the optimal values of the resonance width, were needed
for a more realistic estimation of the dose rate in tumor
delivered by the 33S (n, α) reaction. So, a series of experi-
ments were proposed to INTC committee at CERN with
the intention of clarifying all open questions regarding
this cross-section [19, 20]. Also, an experiment was pro-
posed to the Institut Laue-Langevin (ILL) committee for
the measurement of the thermal point at PF1B line [21].
In the following, the most important results are summa-
rized. Then, the dose rate in ICRU-4 tissue is estimated by
means of Monte Carlo simulations with the present data
and the ENDF evaluation [22].
2 The experiments at CERN and ILL
The first experiment was carried out at Experimental Area
1 (EAR1) of n_TOF-CERN facility, with the aim of re-
solving the discrepancies in the resonance parameters of
the 13.45 keV resonance between Coddens et al. [15] and
Wagemans et al. [2]. EAR1 is 185 m from the neutron
production target, therefore, a high energy resolution can
be achieved. The technical features of the facility and the
characteristics of the neutron beam are described in detail
in [23]. Among the high resolution, other beam charac-
teristic is the large beam aperture, 8 cm diameter, allowing
the use of large thin samples that increase the expected low
count rate in the resonance valleys. Using borated water as
moderator it minimizes neutron capture in hydrogen, and
thus the associated in-beam γ-ray background in neutron
capture cross-section measurements. The most important
consequence for this measurement was a strong reduction
of the thermal peak in the neutron flux. Hence, an ex-
cellent description of the resonances was achieved but the
energy range was restricted from 10 to 300 keV due to the
very low count rate below 10 keV. The cross-section was
obtained using 10B(n, α)7Li standard. The most remark-
able result was that the area of the resonance at 13.45 keV
was a factor 1.5 that of Wagemans et al.. Regarding the
resonance analysis, it was found Γα = 100± 5 eV, in better
agreement with Coddens et al. (83±3 eV) than with Wage-
mans et al. (41 ± 5 eV). All the details of the experiment
and the analysis can be found in [24].
The second experiment was carried out at Experimen-
tal Area 2 (EAR2) of n_TOF-CERN facility, with the aim
of measuring the cross-section below 10 keV for the first
time. EAR2 is located at 20 m from the neutron produc-
tion target. The increase of the neutron flux, a factor 40
overall, represents the main advantage of EAR2 compared
with EAR1. The technical features of EAR2 facility are
described in detail in [25]. The cross-section was obtained
related to the neutron flux. The most important result was
that for the first time the shape of the cross-section was
measured from thermal to 10 keV and a 1/v behavior was
found. The covered energy range was from thermal to 100
keV. The 13.45 keV resonance was resolved with low reso-
lution, however, the area of the resonance was also a factor
1.5 higher than the value of Wagemans et al., confirming
the value obtained at EAR1. The final results of the exper-
iment are in progress because of the ongoing extraction of
the TOF-energy relation. All the details of the experiment
and the analysis can be found in [26].
The third experiment was carried out at PF1B cold
neutron line at ILL [27]. The main objective was to obtain
the thermal cross-section and to use it as a normalization of
the EAR2 data. The cross-section was measured related to
the 10B(n, α)7Li standard with different geometries, as well
as two 33S samples and two 10B samples. For the first sam-
ple and first geometry a preliminary value of 0.25 ± 0.03
barn has been obtained. Figure 1 shows the complete data
measured at n_TOF-CERN normalized from thermal to 10
keV with the preliminary data obtained at ILL.
Figure 1. Experimental data obtained at n_TOF-CERN facility.
From 10 to 300 keV the data were measured at EAR1. From
thermal to 10 keV the data were measured at EAR2. The nor-
malization factor obtained at ILL was applied to the EAR2 data.
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production target, therefore, a high energy resolution can
be achieved. The technical features of the facility and the
characteristics of the neutron beam are described in detail
in [23]. Among the high resolution, other beam charac-
teristic is the large beam aperture, 8 cm diameter, allowing
the use of large thin samples that increase the expected low
count rate in the resonance valleys. Using borated water as
moderator it minimizes neutron capture in hydrogen, and
thus the associated in-beam γ-ray background in neutron
capture cross-section measurements. The most important
consequence for this measurement was a strong reduction
of the thermal peak in the neutron flux. Hence, an ex-
cellent description of the resonances was achieved but the
energy range was restricted from 10 to 300 keV due to the
very low count rate below 10 keV. The cross-section was
obtained using 10B(n, α)7Li standard. The most remark-
able result was that the area of the resonance at 13.45 keV
was a factor 1.5 that of Wagemans et al.. Regarding the
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mans et al. (41 ± 5 eV). All the details of the experiment
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overall, represents the main advantage of EAR2 compared
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the EAR2 data. The cross-section was measured related to
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Figure 1. Experimental data obtained at n_TOF-CERN facility.
From 10 to 300 keV the data were measured at EAR1. From
thermal to 10 keV the data were measured at EAR2. The nor-
malization factor obtained at ILL was applied to the EAR2 data.
3 Dose rate in ICRU-4 tissue with 33S and
13.45 keV neutrons
The calculation of the biological equivalent dose allows
the estimation of the success of a treatment. A correct cal-
culation of the biological dose needs a study of the follow-
ing elements: neutron source, composition and geometry
of the tumor, concentration and biodistribution of the tu-
mor dopant, and kerma rates [7, 28]. Kerma rates are an
efficient way to study the dose because they provide the
absorbed dose which will be supplied by the energy de-









where φ is the neutron flux and µt
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, the coefficient that de-
scribes the mass energy transferred. Kerma coefficients
for neutrons are described based on the number of interac-
tions that occur due to the penetration of neutrons into the
tissue, which are defined as (2):












being L the sum of all materials; j, the sum of the pro-
cesses produced; NL, the density of the material, which is
inversely proportional to the atomic mass; and Ē, the mean
kinetic energy transferred to the charged particles because
of the different processes with cross-section σ. Figure 2
shows the kerma coefficients of the reactions on ICRU-4
tissue [29] considered in the present work.
Figure 2. Kerma coefficients of ICRU-4 tissue for neutrons (vi-
olet, green, light blue, orange and yellow lines), 10B (ENDF/B-
VIII.0) data (black line), 33S (this work data) (red line).
Kerma coefficients for photondepend on the tissue ab-
sorption coefficient. They are calculated using the equa-
tion (3):




where Eγ is the photon energy and
µen
ρ
, the absorption co-
efficient of the selected tissue, taken from NIST [30].
MCNPX code [31] lets simulate the transport and in-
teraction of neutrons with tissue, generating the absorbed
dose. For this, it is necessary a file detailing the geome-
try; in this case, two cylinders, one larger, representing the
head, and another one at a depth of 1 cm, which is the tu-
mor; the materials that fill the geometry are also specified
to the program, ICRU-4 for the head, and for the tumor,
ICRU-4 doped with 10B [7, 28] and 33S [9],
Lee & Zhou [32] showed that for 1920 keV protons
impacting on a thick lithium target, neutrons emitted from
70o − 74o to the proton beam have energies ranging from
0 to 20 keV. The highest probability of obtaining 13.5 keV
is at 70o. In order to estimate the possible use of 33S as
target, it has been considered the case of a pure 13.45 keV
homogeneous disk neutron beam of 1 cm radius impacting
on the tissue located at 70o of the same section. The tissue
contains the proportions of 10B reported in NCT, 40 µg/g
[7], and in the case of 33S, the reported for absorption of
35S in mice, 10 mg/g [9]. The considered neutron flux
was 1010 cm−2·s−1 as reported in [28] and the dose rate is
considered equal to the kerma rate with the approximation
that the energy transferred is equal to the energy absorbed,
as usual in this field [7, 28]. Figure 3 shows the result of
the dose rate as a function of the depth in tissue.
Figure 3. Dose rate due to the incidence of neutrons on: ICRU-
4 (blue line); ICRU-4 with 10B (black line); ICRU-4 with 10B
and 33S (ENDF/B-VIII.0) (green line); ICRU-4 with 10B and 33S
(n_TOF (EAR1 + EAR2) + ILL) (red line); The statistical error
is 1.8% for ICRU-4; 0.6% for ICRU-4 with 10B; 1.9% for ICRU-
4 with 10B and 33S (ENDF/B-VIII.0); and 2.0% for ICRU-4 with
10B and 33S (n_TOF (EAR1 + EAR2) + ILL).
So, the increment in the dose due to the presence of 33S
in the tissue is imperceptibly bigger when the ENDF data
are used. However, when the 33S data of the present work
are used the dose increases considerably. This sets a good
basis for continuing the research on 33S as a cooperative
target for NCT.
4 Conclusions
This work reviews the lastest data for the 33S (n, α)30S i
cross-section. Three experiments were carried out with
different objectives. The first one was performed at the
EAR1 of n_TOF-CERN facility and provided a value for
the Γα parameter of the 13.45 keV resonance, which is the
most important one, close to the transmission measure of
Coddens et al. and a factor 1.5 the value obtained in the
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(n, α) measurement of Wagemans et al. This resonance
is crucial to the possible use of 33S in NCT. The second
experiment was performed at the EAR2 of the n_TOF-
CERN facility and provided for the first time the cross-
section from thermal to 10 keV. Furthermore, the area of
the 13.45 keV resonance agreed with the value obtained at
EAR1, both a factor 1.5 the value of Wagemans et al. The
third experiment was performed at the PF1B line at ILL
nuclear reactor. The aim of the experiment, whose final
analysis is ongoing, is to provide a normalization factor to
the EAR2 data. The value of the cross-section below 10
keV to thermal is crucial to NCT because the moderation
of the neutrons throughout the tissue determines the dose
rate delivered to the tumor in depth.
This study proposes the combined use of 10B and 33S
as targets for the neutrons in NCT, where the novelty
comes from the 33S which has not been used as a target in
clinical trials to date and new data used in dose rate simu-
lations. The simulations consider a setup based on the re-
ported data for the absorption of 10B and 33S and neutron
yield. A simplification has been performed by considering
a monoenergetic neutron beam of 13.45 keV. The results
show that the 33S is a promising possibility for NCT.
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